Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
Isabela Gonçalves LimaIsabele Benck Usiro Cabral da SilvaVitória Carpentieri PípoloVinicius Daher Alvares DelfinoPaulo Roberto BignardiPublished in: Immunopharmacology and immunotoxicology (2024)
These findings suggest that ICI use is associated with an increased risk of AKI and that anti-PD-1 use is associated with a higher incidence of renal adverse events than programmed cell death ligand 1 monoclonal antibody (anti-PD-L1). Studies with adequate power and well-defined criteria for acute interstitial nephritis, nowadays taken as a synonym for AKI related to ICI, are necessary.